Results of bilateral thoracoscopic splanchnicectomy in a patient with diabetic neuropathy of the coeliac plexus; reduction of 2,000 mg daily dose of morphine: a case report by Malec-Milewska, Małgorzata et al.
www.advpm.eu 107
Case report
Małgorzata Malec-Milewska1, Iwona Kolęda1, Agnieszka Sękowska1, Adam Ciesielski2,
Jerzy Wordliczek3, Jacek Jastrzębski1
1Pain Clinic at the Department of Anaesthesiology and Intensive Care, The Medical Centre of Postgraduate Education, Warsaw
2Department of Surgery, The Medical Centre of Postgraduate Education, Warsaw
3Department of Pain Medicine and Palliative Care of Jagiellonian University Medical College in Cracow
Results of bilateral thoracoscopic
splanchnicectomy in a patient
with diabetic neuropathy
of the coeliac plexus; reduction
of 2,000 mg daily dose
of morphine: a case report
Abstract
We report the case of a 32-year-old patient with a long history of diabetes mellitus Type I complicated by
coeliac plexus neuropathy. A strong pain syndrome of neuropathic type led to an addiction to parenterally
applied morphine. The patient consumed 2,000 mg of intravenous or subcutaneous morphine per day.
Thanks to the cooperation of three centres, the Pain Clinic at the Department of Anaesthesiology and
Intensive Therapy of The Medical Centre of Postgraduate Education (CMKP) in Warsaw, the Department of
Surgery CMKP in Warsaw, and the Pain Clinic and Palliative Care Clinic of Jagiellonian University Medical
College (CMUJ) in Cracow, it was possible to stop the opioid intake completely.
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Introduction
Diabetes mellitus Type I is a disease based on
total or near-total lack of insulin, which is caused by
the destruction of the pancreatic b cells in the islet
of Langerhans by an autoimmune process and which
requires continuous substitution of this hormone.
Some role is also played by genetic factors: 20% of
patients have a positive family history for this dis-
ease and over 90% of patients have proven to be
carriers of antigen DR3 and/or DR4. Treatment of
Type I diabetes is based on insulin intake in the
manner most resembling its physiological produc-
tion. However, there are difficulties in treating dia-
betes due to an inability to imitate fully the physio-
logical fluctuations of serum insulin concentration.
Late complications of diabetes are divided into two
groups. The first group is associated with large ves-
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sels, such as coronary heart disease due to athero-
sclerosis, obliterative atherosclerosis of peripheral
vessels, cerebral vascular disease and cerebral is-
chaemic stroke. The other group involves small ves-
sels and includes retinopathy, nephropathy and neu-
ropathy. Scientific research supports the view that
long-term complications related to small vessels are
due to chronic hyperglycaemia. Therefore, improp-
er treatment of diabetes predisposes patients for
these complications. Diabetic neuropathy is one of
the most common late complications of diabetes
mellitus. In some patients neuropathy may be asso-
ciated with disturbances within the autonomic ner-
vous system [1].
Case report
A 32-year-old female patient with a history of
diabetes since the age of eight. The diabetes was
complicated by bilateral proliferative retinopathy,
nephropathy and neuropathy of the coeliac plexus
— Group III on the Mogensen scale — with a strong
pain syndrome. Glaucoma of the left eye with par-
tial loss of vision in that eye due to optic nerve
atrophy. Caesarean section delivery. Duodenal ul-
cer. Treated with very high doses of strong opioids
without success.
The patient was referred by her internist to the
Pain Clinic at the Department of Anaesthesiology
and Intensive Care Medicine in Warsaw. The reason
for the referral was very strong pain localized in the
upper abdomen which was not responding to strong
opioids. On the day of admission on 8 August 2006,
she was suffering from strong pain and reported its
level at 10 on an 11-point numerical rating score
(NRS); the NRS is a self-reporting measure of pain
intensity where 0 means no pain and 10 relates to
the worst pain imaginable. The pain was constant
and accompanied by paroxysmal nausea and vom-
iting. The pain first started in July of 2004. Accord-
ing to the patient the onset of pain was strictly
associated with the beginning of pregnancy. Initial-
ly the pain was paroxysmal in nature. Each pain
attack would last for a week and was accompanied
by persistent nausea and vomiting, the gastric con-
tents periodically stained with fresh blood. The in-
tensity of pain at the time of the attacks was reach-
ing a score of 10 on the NRS scale. Periods between
the attacks and vomiting were 6 to 9 days long.
Starting in the eighth month of pregnancy, the char-
acter of the pain changed to being constant but the
nausea and vomiting stayed persistently paroxys-
mal. The pregnancy ended on 14 March 2005 with
the delivery of a healthy son. Immediately after the
Caesarian section delivery there was a 10-day cessa-
tion of pain attacks.
Prior to her admittance to the Pain Clinic the
patient was treated without effect with NSAID, weak
opioids such as tramadol 600 mg IM per day and
buprenorphine patches at 130 mg/h. She was then
treated with pethidine IM 400–500 mg a day for 4
months and transdermic fentanyl at maximum dose
of 300 mg/h. Finally, parenteral morphine was first
applied intravenously and later, due to problems
with the intravenous method, subcutaneously in
increasing in strength doses.
At the time of admittance to the Pain Clinic the
patient was on 2,000 mg of morphine per day. The
daily dose was estimated by analyzing data on the
number of written and paid for prescriptions re-
ceived from pharmaceutical monitoring. Morphine
was prescribed to the patient by her husband, a
specialist in internal medicine, who had been treat-
ing his wife himself for two years without any con-
sultation with pain specialists. The patient admit-
ted to a daily dose of morphine of 700 mg, applied
5 times at 140 mg doses. Her husband stated that
his wife had not been exceeding a daily dose of 200
mg subcutaneously or 80 mg intravenously. No ini-
tiation of treatment with co-analgetics commonly
applied in neuropathic pain treatment had been
attempted.
Results of diagnostic tests carried out prior to
the first visit at the pain clinic are as follows:
1. Ht — 35%, Hg — 11.5 g/dl, Na — 135 mmol/l, K
— 3.6 mmol/l, Ca total — 2.4 mmol/l, coagulo-
gram: APTT — 30.1 s, INR — 1.1, gasometry pH
— 7.44, p O2 — 68.7 mm Hg, PCO2 — 38.4 mm
Hg, BE + 1.5, glycaemia at 42 j insulin/day: 61–
180 mg%.
2. Electrogastrography (22.04.05) — advanced ab-
normalities on record in the character of dyski-
nesis with distinctive bradygastria.
3. Ultrasound of abdomen — liver not enlarged, of
normal echogenicity. Wall thickening of gall blad-
der to about 4 mm. Normal pancreas and spleen.
Kidneys of normal size, properly localized, of nor-
mal echogenicity. No dilatation of pelvis of calic-
es. Normal thin-walled urinary bladder.
At the Pain Clinic the patient was commenced
on the following: venlafaxine 75 mg/day, gabap-
entin (Neurontin) 3 ¥ 100 — 3 ¥ 300 mg, mebev-
erine HCl 2 ¥ 1 tablet, lactulose 3 ¥ 15 ml, ome-
prazol 2 ¥ 20 mg, chlorpromazine 2.5 mg if vom-
iting persists. Additional advice included the fol-
lowing: prophylaxis of constipation, 6 easily-digest-
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ible meals a day, control gastroscopy in order to
exclude active peptic ulcer and gastro-oesophageal
reflux and gynaecologist-endocrinologist consul-
tation in order to diagnose menstruation prob-
lems. Gastro-esophageal reflux, active duodenal ul-
cer, oesophageal hiatal hernia, porphyria and thy-
roid hormonal imbalance were all excluded. Gas-
troscopic examination results: “Esophagus with-
out pathologic changes. Ventricular mucus pale,
atrophic. Prepyloric part congested. Pylorus nar-
row, permeable. Duodenal bulb and its distal part
without pathological changes”.
The patient was referred to the Department of
Pain Treatment and Palliative Care of CMUJ in Cra-
cow, where she stayed from 9 to 18 October 2006.
On admittance to the hospital she was experienc-
ing strong pain localized in the upper abdomen
and, in order to settle, she required a constant in-
travenous infusion of morphine at the dose of 1,000
mg per day. Pain was accompanied by nausea and
vomiting “coffee-ground” contents. Surgical con-
sultation: patient suffering a great deal, lying on
one side with aggravated vomit reflux.
On palpation abdomen soft, peristalsis present.
Lack of bleeding in gastroscopy but presence of
“coffee-ground” content; hysterical reaction to ex-
amination. Examination of duodenum was not pos-
sible. According to the surgeon's advice, null diet,
drip infusion and antiemetics such as ondansetron,
metoclopramide and haloperidol were administered.
After 2 days, the vomiting stopped but the patient
still required morphine infusion. On 16 October
2006, a diagnostic/prognostic coeliac plexus block-
ade was performed under X-ray control. The block-
ade was carried out under a local anaesthetic and
steroid. Following the procedure the pain subsided
and conversion to oral intake of morphine was at-
tempted, unfortunately without success. One posi-
tive effect of the block was an indication of bilateral
thoracoscopic splanchnicectomy. The previously rec-
ommended treatment was continued. It included
the following: gabapentin, venlafaxine, omeprazol,
lactulose and insulin, and additionally cisapride 3 ¥
10 mg 15 min before meals, pentoxifylline 3 ¥ 100
mg, alpha-lipoic acid 2 ¥ 600 mg added by a dia-
betologist. The procedure of the thoracoscopic
splanchnicectomy was undertaken at the Depart-
ment of Surgery at CMKP on 2 November 2006. The
surgery was performed on the patient while she
was face-down under general anaesthesia — TIVA
with propofol. The face-down position allows for
easy access to both pleural cavities and the patient
does not need repositioning on the operating table
during the procedure. The surgery itself and the
perioperative period were free of complication. It
was possible to achieve complete pain alleviation
and a reduction in the frequency of vomiting to one
or only a few episodes per day over the following
three weeks. Following the surgery, the parenteral
dose of morphine was reduced gradually over a few
days to 100 mg a day. It was not possible to reduce
the daily dose below 60 mg or to switch the patient
to oral therapy, despite a number of consultations
with the Addiction Clinic at the Institute of Psychia-
try and Neurology in Warsaw and numerous con-
sultations with a psychotherapist. The patient had
been constantly demanding parenteral dosing of
opioids. The difficulty in treating the patient was
due to weak cooperation from the family; especially
from the patient's husband. Since no ambulatory
treatment was possible the patient was once again
referred to the Department of Pain Medicine and
Palliative Care in Cracow, where she stayed from 27
November 2007 to 11 January 2008. According to
the psychiatric consultation: “Patient well-oriented
with good but superficial verbal contact. She com-
plains of anxiety and frequent awakenings at night.
Addicted to morphine, currently reducing the dose”.
Treatment with methadone was implemented. The
dose of methadone at the end of the hospitaliza-
tion was 3 ¥ 15 ml with the recommendation of
gradual reduction, which was possible to achieve.
In agreement with the psychiatrist, pharmacologi-
cal treatment was changed to the chrono form of
valproic acid 2 ¥ 500 mg, pernazine 25 ¥ 25 ¥ 50
mg, atorvastatine 20 mg, ramipril 2.5 mg at night.
Treatment in this form was continued. Recommen-
dations for the future were a total ban on the
parenteral intake of opioids.
Improper management of neuropathic pain may
lead to addiction to opioids. Thanks to a proper
diagnosis and the complete reduction of pain, it
was possible to reduce the patient's addiction to
high doses of morphine.
Discussion
Diabetes mellitus Type I is a disease caused by
destruction of the pancreatic b cells in the islet of
Langerhans by an autoimmune process, leading to
a total lack of insulin which requires continuous
hormonal substitution. Vascular complications of
diabetes may be divided into non-specific macroan-
giopathy and microangiopathy, the latter being spe-
cific to diabetes and characterized by a thickening
of the basement membrane of the capillaries. It
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seems that hyperglycaemia leading to the glycation
of proteins within the basement membrane plays
some role in the process resulting in microangiopa-
thy. This conclusion was drawn based on the fact
that the thickness of the basement membrane cor-
relates to the duration of the diabetes. Microangi-
opathy may lead to necrosis of peripheral tissues
even in the presence of a peripherally-detected pulse.
With both types of diabetes, diabetic nephropathy
appears in approximately 35% of patients after 25
years of illness. It may lead to severe kidney failure
requiring dialysis. DM I leads to glomerulosclerosis
— Kimmelstiel-Wilson syndrome. Our patient had
been diabetic for 24 years and had developed dia-
betic nephropathy. Diabetic retinopathy comes af-
ter 15 years of illness with Type I in 90% of patients
and in 25% of those with Type II. Angiogenesis is a
pathological process due to the production of
growth factors on the basis of metabolic distur-
bances. The disease may take the course of simple
retinopathy or proliferative retinopathy. The former
is characterized by angiogenesis within the optic
nerve head or in the adjacent retina. Angiogenesis
may also take place in the corpus vitreum. Late com-
plications include retinal separation and glaucoma
[1]. The reported case had both disorders: prolifera-
tive retinopathy and glaucoma. Diabetic neuropa-
thy is valued at 50% after 10 years of illness. Patho-
genesis of neuropathy remains unclear. It is pro-
posed that it is the result of a disorder in the micro-
circulation within nerves and the metabolic distur-
bances in diabetes. The most common type of poly-
neuropathy is peripheral sensory and motor neur-
opathy, which particularly affects the distal parts of
the limbs. It manifests itself by symmetrical pares-
thesias, particularly of the lower limbs and feet —
burning feet syndrome — and bilateral loss of Achil-
les tendon reflexes. The second-most common dia-
betic neuropathy is autonomic neuropathy. It is the
consequence of lesions within the sympathetic and
parasympathetic autonomic nervous system [1]. For
instance, it may involve the coeliac plexus, which is
of mixed type, built from both sympathetic and
parasympathetic nerve fibres of the vagal nerve.
This form of neuropathy was the most probable
cause of pain in our patient. Neuropathy can also
involve the digestive tract due to lesions within the
parasympathetic system. It may lead to disturbanc-
es in motor function of the oesophagus, dysphagia
as well as gastroparesis [1]. Impaired functioning
of the digestive system was also described in the
case of our patient. It seems that she suffered from
neuropathic pain originating in the coeliac plexus.
Neuropathic pain is the pathological type that is
initiated or caused by primary damage to the cen-
tral or peripheral nervous systems. The definition of
neuropathic pain includes various pain syndromes
which lack a common aetiology and do not result
from the same kind of disorder within the auto-
nomic system. Despite a different aetiology and vari-
ability in lesions, many of the neuropathic pain syn-
dromes have common clinical features, such as a
lack of easily-noticeable damage, a paradoxical com-
bination of sensory depletion and hyperalgesia with-
in the painful area, and paroxysmal pain which may
become constant. Although there are common clin-
ical features for various neuropathic pain syndromes,
which could suggest similar pathogenic mechanisms
resulting from hyperexcitability of peripheral and
central neurons, the pathogenesis of this type of
pain might be the result of many additional factors,
such as a receptor component or sympathetic sys-
tem dependency. All these factors are responsible
for a highly variable success rate in the treatment of
neuropathic pain [2, 4].
The treatment optimalization route chosen for
patients with neuropathic pain is based on an un-
derstanding of the mechanisms responsible for in-
ducing pain in an individual patient and the choice
of treatment specific to a particular mechanism.
The results of experimental research point to at least
three components, which coexist as to which is re-
sponsible for the initiation of neuropathic pain. The
first component involves changes in the electrical
excitability of cellular membranes of the damaged
axon or spinal ganglion of the first afferent neuron.
The second involves changes in the processing of
received signals in the posterior horn of the spinal
cord. The third points to the higher floor of the
central nervous system, where disintegration of pro-
grammed and coordinated responses to stimuli af-
fects the system's integrity. Despite the similarities
in pathogenesis and symptoms of neuropathic pain,
regardless of the type of damage, the classification
of neuropathic pain is most frequently based on the
probable cause of pain in an individual patient. This
approach allows implementation of optimal thera-
py; invasive techniques are as worth considering as
treatment with pharmaceuticals with different ac-
tion mechanisms [3-5]. The effectiveness of classi-
cal analgetics, including the most commonly-ad-
ministered NSAID, is relatively small. These were
not effective in the case of our patient. In the US
over 50% of patients with neuropathic pain receive
weak or strong opioids. The effectiveness of opioids
in the treatment of neuropathic pain has been prov-
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en but varies from being very high, even though
applied in much higher doses than in nociceptive
pain, to completely ineffective. In the case of a com-
plete lack of noticeable therapeutic success after
the implementation of opioid treatment, withdraw-
ing from the treatment is advised. If unsuccessful
opioid therapy is not abandoned soon enough, it
can potentially, in only a short time, cause addic-
tion to this group of pain medication [4]. In the
case of our patient, tramadol, buprenorphine, pethi-
dine and fentanyl appeared to be ineffective, and
finally the administered morphine led to the neces-
sity of a high parenteral dosage intake in a short
period of time. Before her arrival at the Pain Clinic,
no one had tried the other groups of medication
which are recommended in the treatment of neuro-
pathic pain and are characterized by low NNT (Num-
ber Needed to Treat). The NNT relates to the num-
ber of patients who are given a particular agent in
order to achieve a 50% reduction in pain in one of
them at the 95% confidence interval. The lowest
NNT belongs to tricyclic antidepressant drugs with
amitryptilline (NNT = 2.4), anticonvulsants (NNT =
2.2–3.8), carbazepine, oxycarbamazepine, phenyto-
in, gabapentin, pregabalin, lamotrigine, valproic
acid, and local anaesthetics [4]. At the Pain Clinic
our patient was started on gabapentin at 900 mg a
day; later on, valproic acid chrono at 600 mg per
day and venlafaxine at 75 mg a day were added.
Amitryptilline was not administered due to the his-
tory of glaucoma. Unfortunately, this treatment has
brought no success.
Neurophysiological and neuroimmunological
tests for the mechanisms of pain have pointed to
the important role of the autonomic system in the
modulation of the nociceptive process and has laid
new bases for the treatment of pain. Neurodestruc-
tive procedures on the sympathetic system turned
out to be successful in treating many pain syn-
dromes, especially in the case of the coeliac plexus
[6]. In the case of the patient presented here, a
diagnostic-prognostic blockade of the coeliac plex-
us with a local anaesthetic and steroid was first
performed. Only after receiving a satisfactory result
of the blockade was the decision made to perform
bilateral thoracoscopic splanchnicectomy. The pro-
cedure is based on sectioning the coeliac nerves
within the thorax. Two trocars are inserted into the
thoracic cage: one just below the scapular angle,
the other into the intercostal space below and clos-
er to the spine. Under visual control, following ear-
lier lung deflation using a harmonic knife, a cut in
the visible nerve branches is made. It is usually pos-
sible to cut 4 to 7 branches on each side. The proce-
dure is always started on the left-hand side since it
is the more difficult side on which to operate and is
more time-consuming because of the less transpar-
ent pleura. After the procedure on the left is fin-
ished the lung is expanded and left without drain-
age. Next, the procedure is carried out on the right-
hand side. The time required for the procedure on
each side is approximately 10–15 minutes. Follow-
ing the surgery, the double-lumen endotracheal tube
was replaced by a standard endotracheal tube and
the patient was put on controlled pressure support
ventilation in order to ensure proper lung expan-
sion [7].
As a result of the procedure our patient was free
of pain and it very quickly became possible to re-
duce her need for morphine from 2,000 mg to 100
mg a day. The minimal daily dose of morphine was
reduced to 60 mg a day but complete elimination
of the opioid from the treatment or the changing of
its route to being parenteral or subcutaneous could
not be achieved. Difficulties in managing the pa-
tient on an ambulatory basis resulted from the lack
of cooperation from the patient's family, especially
her husband who, despite being informed of the
strategy behind the treatment, persisted in increas-
ing the subcutaneous dosage of morphine.
In managing intense chronic non-cancer pain we
can reach for strong opioids, but continuation of
the opioid-based therapy is justified only in case
they had been proven beneficial. The route of ad-
ministration for the opioids should be either enteral
or subcutaneous. Each doctor prescribing opioids
should be aware of the risk factors and methods for
diagnosing opioid dependency [8]. The patient's
husband was not cautious enough and made a num-
ber of errors in managing her pain which, as a con-
sequence, led to his wife's addiction to opioids. Fi-
nally, the plan to eliminate the intake of opioids by
our patient completely was undertaken in the De-
partment of Pain Medicine and Palliative Care of
CMUJ in Cracow.
There are two major routes of treatment for opi-
oid addiction: one based on drugs which reduce
the discomfort due to the discontinuation of opioid
intake; and the other based on agents that do not
reduce addiction but lower opioid activity. Substi-
tutive treatment is an oft-employed method of ad-
diction therapy with the use of a substance having
an opioid-like course of action and, thus, being the
agonist of the opioid receptor. This agonist is ad-
ministered to the addicted patient in order to trans-
form the addiction to a more controllable form. The
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managing of addiction with an agonist prevents
abstinence syndrome, reduces the health and social
consequences of addiction and, implemented in the
proper dosage, lowers the psychological need for
opiates. Methadone is one example of an opioid
agonist. Conditions for methadone therapy have
been established by the Ministry of Health in two
sets of regulation in 1999 and 2004 [9]. Our patient
underwent this therapy and positive results were
achieved.
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